Scinai Immunotherapeutics Ltd (SCNI) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access SCNI Annual Income Statement →
Quarterly income statement trends provide context on Scinai Immunotherapeutics Ltd's margins, operating leverage, and earnings trajectory.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2025)
Q4 2025
0 0 0 (Dec 31 2023)
Revenues
Total Revenue1.31
Costs & Expenses
Cost of Goods and Services Sold3.96
Gross Profit-2.65
Selling, Administration, Marketing2.52
Research and Development Expense2.37
Other Operating Expense / -Income0.00
Total operating costs including COS8.85
Operating income / -loss-7.54
Net Interest Expense / -Income0.00
Investment Income, Net0.00
Other loss / -income0.77
Total costs & expenses9.62
Income & Taxes
Income / -loss before income taxes-8.31
Income after income taxes-8.31
Income / -loss from continuing operations-8.31
Net income / -loss-8.31
Income / -loss to shareholder-8.31
EBIT-8.31
EBITD-6.89
EBITDA-6.89
Earnings Per Share
Basic EPS (excl. extra items)0.00
Basic Net EPS0.00
Basic shares outstanding (Mill. of Units)0.00
Diluted Net EPS0.00
Diluted average shares (Mill. of Units)0.00
4 historic quarters locked

Sign in to unlock the full Scinai Immunotherapeutics Ltd income statement history.

About SCNI Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.